Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
RPL3 N/A
Sequence Length (AA) Molecular Weight (Da)
403 46109
Protein Name
60S ribosomal protein L3
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MSHRKFSAPR HGSLGFLPRK RSSRHRGKVK SFPKDDPSKP VHLTAFLGYK
60 70 80 90 100
AGMTHIVREV DRPGSKVNKK EVVEAVTIVE TPPMVVVGIV GYVETPRGLR
110 120 130 140 150
TFKTVFAEHI SDECKRRFYK NWHKSKKKAF TKYCKKWQDE DGKKQLEKDF
160 170 180 190 200
SSMKKYCQVI RVIAHTQMRL LPLRQKKAHL MEIQVNGGTV AEKLDWARER
210 220 230 240 250
LEQQVPVNQV FGQDEMIDVI GVTKGKGYKG VTSRWHTKKL PRKTHRGLRK
260 270 280 290 300
VACIGAWHPA RVAFSVARAG QKGYHHRTEI NKKIYKIGQG YLIKDGKLIK
310 320 330 340 350
NNASTDYDLS DKSINPLGGF VHYGEVTNDF VMLKGCVVGT KKRVLTLRKS
360 370 380 390 400
LLVQTKRRAL EKIDLKFIDT TSKFGHGRFQ TMEEKKAFMG PLKKDRIAKE
403
EGA

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for non-CPTAC-6121 Collapse assay details

Data source: Panorama

Official Gene Symbol
RPL3
Peptide Sequence
FIDTTSK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
367
Peptide End
373
CPTAC ID
non-CPTAC-6121
Peptide Molecular Mass
810.4123
Species
Homo sapiens (Human)
Assay Type
Direct MRM-MS
Matrix
Bovine Serum Albumin
Submitting Laboratory
McGill University
Submitting Lab PI
Christoph H. Borchers, Gerald Batist

Publication

View Details (opens in a new window)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Agilent 6495B QQQ-MS
Internal Standard
Standard Isotope labeled internal standard peptides with 13Cx, 15Ny (R+10 or K+8)
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Infinity 1290
Column Packing
commercial (Agilent ZORBAX Eclipse Plus C18)
Column Dimensions
4.6 mm × 150 mm, (5 µm)
Flow Rate
0.4 mL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b2 (1+) 5.4 4.4 4 5.6 5.5 4.7 7.8 7 6.2 16 16 17
y2 (1+) 10.1 4.1 3.3 11.8 5 4.4 15.5 6.5 5.5 16 16 17
y4 (1+) 9.1 4.9 4.6 12.2 5.4 4.7 15.2 7.3 6.6 16 16 17
y5 (1+) 7 3.1 3.8 6.9 4.3 4.8 9.8 5.3 6.1 16 16 17
y6 (1+) 9.8 4.4 4.3 7.5 5.4 5.9 12.3 7 7.3 16 16 17
sum 4.9 2 2.4 4.7 2.7 3 6.8 3.4 3.8 16 16 17


Stability

Data source: Panorama

Fragment ion / Transition control_intra_CV actual_temp_intra_CV frozen_intra_CV FTx1_intra_CV FTx2_intra_CV
b2 (1+) 6.3 4.6 5.7 7.8 2.7
y2 (1+) 2.6 7.6 6.8 12.2 7
y4 (1+) 8 5.9 3.4 7.9 1
y5 (1+) 6.2 7.4 5.5 1.9 1.6
y6 (1+) 11.4 10.9 9.3 9.3 3.1
sum 5.3 4 2.9 2.5 0.9
Fragment ion / Transition all_intra_CV all_inter_CV
b2 (1+) 5.3 6.7
y2 (1+) 7.3 6.3
y4 (1+) 5.3 4.8
y5 (1+) 5 5.2
y6 (1+) 9.1 7.7
sum 3.3 3.7

Endogenous

Data source: Panorama

Fragment ion / Transition intra_CV inter_CV total_CV
b2 (1+) 6.6 29 29.7
y2 (1+) 20.7 19.1 28.2
y4 (1+) 8.1 26.1 27.3
y5 (1+) 18 34.3 38.7
y6 (1+) 5.5 17.9 18.7
sum 10.5 28.5 30.4

Additional Resources and Comments